Pieris Pharma (PIRS) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2015
August 12, 2015 5:51 PM EDTFREISING, GERMANY -- (Marketwired) -- 08/12/15 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today reported financial results for the second quarter of 2015, and provided an update on the Company's recent developments.
"Over the past six months, Pieris has made significant progress across the board," said Stephen Yoder, President and CEO. "In July we closed a public offering of our common... More
